Top

Published in:

01-02-2009 | Laboratory and Translational Research

Sulforaphane Stimulates Activation of Proapoptotic Protein Bax Leading to Apoptosis of Endothelial Progenitor Cells

Authors: Takeshi Nishikawa, Nelson H. Tsuno, Takeshi Tsuchiya, Satomi Yoneyama, Jun Yamada, Yasutaka Shuno, Yurai Okaji, Junichiro Tanaka, Joji Kitayama, Koki Takahashi, Hirokazu Nagawa

Published in: Annals of Surgical Oncology | Issue 2/2009

Abstract

Sulforaphane (SUL) is an isothiocyanate naturally present in widely consumed vegetables, particularly in broccoli. SUL has recently been focused as a result of its inhibitory effects on tumor cell growth in vitro and in vivo. We used endothelial progenitor cells (EPCs) as an in vitro model to investigate the effect of SUL on the various steps of vasculogenesis and angiogenesis. Peripheral blood mononuclear cells from blood of normal human volunteers were plated on fibronectin-coated 100 mm dishes and incubated for 7 days. The viability of EPCs, treated with SUL at different doses, was assessed by MTS assay. Cell apoptosis was analyzed by flow cytometry. To determine the relative contributions of caspase-8 and caspase-9 pathways to SUL-induced apoptosis, the effect of caspase inhibitors was determined. The expression of apoptosis-related proteins (Bax, Bcl-2) was investigated by Western blot test. Finally, the effect of SUL on the ability of EPCs to form vascular-like structures on Matrigel was investigated. We clearly demonstrated that SUL induced the dose-dependent inhibition of EPCs’ viability by induction of apoptosis. All caspases (caspase-3, −8, and −9) were activated during apoptosis induction by SUL, but the effect of caspase-9 was more prominent than that of caspase-8. Also, the expression of Bax was upregulated by SUL treatment. In addition to apoptosis induction, SUL dose-dependently inhibited the tube-like formation by EPCs on Matrigel. The present results demonstrate the antivasculogenic/antiangiogenic activity of SUL in vitro and open premise for the use of SUL as a multipotent anticancer agent that targets both cancer cells and the angiogenic endothelium.

Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931–4.PubMed

Risau W, Sariola H, Zerwes HG, et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development. 1988;102:471–8.PubMed

Okaji Y, Tsuno NH, Saito S, et al. Vaccines targeting tumour angiogenesis—a novel strategy for cancer immunotherapy. Eur J Surg Oncol. 2006;32:1–8.CrossRef

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.PubMedCrossRef

Asahara T, Murohara T, Sullivan, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964–7.

Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow–derived endothelial progenitor cells. EMBO J. 1999;18:3964–72.PubMedCrossRef

Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA. 2000;97:3422–7.PubMedCrossRef

Peters BA, Diaz LA Jr, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11:261–2.PubMedCrossRef

Hutter R, Carrick FE, Valdiviezo C, et al. Vascular endothelial growth factor regulates reendothelialzation and neointima formation in a mouse model of arterial injury. Circulation. 2004;110:2430–5.PubMedCrossRef

10.

Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999–1007.PubMedCrossRef

11.

Rehman J, Li J, Orschell CM, et al. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164–9.PubMedCrossRef

12.

Asakage M, Tsuno NH, Kitayama J, et al. Early-outgrowth of endothelial progenitor cells can function as antigen-presenting cells. Cancer Immunol Immumother. 2006;55:708–16.CrossRef

13.

Kohlmeier L, Mendez M. Controversies surrounding diet and breast cancer. Proc Nutr Soc. 1997;56:369–82.PubMedCrossRef

14.

Zhang SM, Hunter DJ, Rosner BA, et al. Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin’s lymphoma among women. Cancer Epidemiol Biomarkers Prev. 2000;9:477–85.PubMed

15.

Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst. 2000;92:61–8.PubMedCrossRef

16.

Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev. 2000;9:795–804.PubMed

17.

Hecht SS. Inhibition of carcinogenesis by isothiocyantes. Drug Metab Rev. 2000;32:395–411.PubMedCrossRef

18.

Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry. 2001;56:5–51.PubMedCrossRef

19.

Gao X, Dinkova-Kostova AT, Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc Natl Acad Sci USA. 2001;98:15221–6.PubMedCrossRef

20.

Fahey JW, Zhang Y, Talalay P. Broccoli sprout: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogen. Proc Natl Acad Sci USA. 1997;94:10367–72.PubMedCrossRef

21.

Zhang Y, Talalay P, Cho CG, et al. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA. 1992;89:2399–403.PubMedCrossRef

22.

Gamet-Payrastre L, Li P, Lumeau S, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000;60:1426–33.PubMed

23.

Bonnesen C, Eggleston IM, Hayes JD. Dietary indoles and isothiocyanates that are genereted from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res. 2001;61:6120–30.PubMed

24.

Pappa G, Bartsch H, Gerhause C. Biphasic modulation of cell proliferation by sulforaphane at physiologically relevant exposure times in a human colon cancer cell line. Mol Nutr Food Res. 2007;51:977–84.PubMedCrossRef

25.

Singh SV, Herman-Antosiewicz A, Singh AV, et al. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem. 2004;279:25813–22.PubMedCrossRef

26.

Chiao JW, Chung FL, Kancherla R, et al. Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. Int J Oncol. 2002;20:631–6.PubMed

27.

Shan Y, Sun C, Zhao X, et al. Effect of sulforaphane on cell growth, G(0)/G(1) phase cell progression and apoptosis in human bladder cancer T24 cells. Int J Oncol. 2006;29:883–8.PubMed

28.

Fimognari C, Nusse M, Berti F, et al. Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed human T lymphocytes. Cell Mol Life Sci. 2002;59:2004–12.PubMedCrossRef

29.

Asakage M, Tsuno NH, Kitayama J, et al. Sulforaphane induces inhibition of human umbilical vein endothelial cells proliferation by apoptosis. Angiogenesis. 2006;9:83–91.PubMedCrossRef

30.

Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885–90.PubMedCrossRef

31.

Hecht SS. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J Nutr. 1999;129:768S–74S.PubMed

32.

Talalay P, Zhang Y. Chemoprotection against cancer by isothiocyanates and glucosinolates. Biochem Soc Trans. 1996;24:806–10.PubMed

33.

Bertl E, Bartsch H, Gerhauser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther. 2006;5:575–85.PubMedCrossRef

34.

Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309–12.PubMedCrossRef

35.

Wolter KG, Hsu YT, Smith CL, et al. Movement of bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 1997;139:1281–92.PubMedCrossRef

36.

Pastorino JG, Chen ST, Tafani M, et al. The overexpression of bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem. 1998;273:7770–5.PubMedCrossRef

37.

Narita M, Shimizu S, Ito T, et al. Bax interacts with permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA. 1998;95:14681–6.PubMedCrossRef

38.

Granville DJ, Carthy CM, Hunt DW, et al. Apoptosis: molecular aspects of cell death and disease. Lab Invest. 1998;78:893–913.PubMed

39.

Yang YM, Conaway CC, Chiao JW, et al. Inhibition of benzo(a)pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and phenethyl isotiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res. 2002;62:2–7.PubMed

40.

Matsuda K, Yoshida K, Taya Y, et al. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res. 2002;62:2883–9.PubMed

41.

Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 1999;399:483–7.PubMedCrossRef

42.

Kluck RM, Bossy-Wetzel E, Green DR, et al. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132–6.PubMedCrossRef

43.

Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776–9.PubMedCrossRef

44.

Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434–8.PubMedCrossRef

45.

Ishida A, Ohya Y, Sakuda H, et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improve limb ischemia. Circ J. 2005;69:1260–5.PubMedCrossRef

46.

Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017–24.PubMedCrossRef

47.

Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567–78.PubMedCrossRef

48.

Sata M. Molecular strategies to treat vascular diseases: circulating vascular progenitor cell as a potential target for prophylactic treatment of atherosclerosis. Circ J. 2003;67:983–91.PubMedCrossRef

49.

Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+) AC133(+) endothelial precursor cells. Circ Res. 2001;88:167–74.PubMed

50.

Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103:634–7.PubMed

51.

Rausher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003;108:457–63.CrossRef

52.

Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1–7.PubMedCrossRef

53.

Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.PubMedCrossRef

54.

Choi JH, Kim KL, Huh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004;24:1246–52.PubMedCrossRef

55.

Okaji Y, Tsuno NH, Kitayama J, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 2004;95:85–90.PubMedCrossRef

56.

Tsuchiya T, Okaji Y, Tsuno NH, et al. Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. Cancer Sci. 2005;96:784–90.PubMedCrossRef

57.

Yoneyama S, Okaji Y, Tsuno NH, et al. A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. Eur J Surg Oncol. 2007;1–8.

58.

Zhang Y, Kensler TW, Cho CG, et al. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA. 1994;91:3147–50.PubMedCrossRef

59.

Zhang Y, Talalay P. Mechanism of differential potencies of isothiocyantes as inducers of anticarcinogenic Phase 2 enzymes. Cancer Res. 1998;58:4632–9.PubMed

60.

Prestera T, Talalay P. Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA. 1995;92:8965–9.PubMedCrossRef

61.

Ye L, Zhang Y. Total intracellular accumulation levels of dietary isothiocyanates determine their activity in elevation of cellular glutathione and induction of phase2 detoxification enzymes. Carcinogenesis. 2001;22:1987–92.PubMedCrossRef

62.

Wattenberg LW. Inhibitory effects of benzyl isothiocyanate administered shortly before diethlnitrosamine or benzo(a)pyrene on pulmonary and forestomach neoplasia in A/J mice. Carcinogenesis. 1987;8:1971–3.PubMedCrossRef

63.

Jiao D, Yu MC, Hankin JH, et al. Total isothiocyanate contents in cooked vegetables frequently consumed in Singapore. J Agric Food Chem. 1998;46:1055–8.CrossRef

64.

Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta. 2002;316:43–53.PubMedCrossRef

Title: Sulforaphane Stimulates Activation of Proapoptotic Protein Bax Leading to Apoptosis of Endothelial Progenitor Cells
Authors: Takeshi Nishikawa
Nelson H. Tsuno
Takeshi Tsuchiya
Satomi Yoneyama
Jun Yamada
Yasutaka Shuno
Yurai Okaji
Junichiro Tanaka
Joji Kitayama
Koki Takahashi
Hirokazu Nagawa
Publication date: 01-02-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-0215-5

At a glance: The STEP trials

Springer Medicine

Sulforaphane Stimulates Activation of Proapoptotic Protein Bax Leading to Apoptosis of Endothelial Progenitor Cells

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Prognostic Role of PGE2 Receptor EP2 in Esophageal Squamous Cell Carcinoma

Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Cytoreductive Surgery and Continuous Hyperthermic Peritoneal Perfusion in Patients with Mesothelioma and Peritoneal Carcinomatosis: Hemodynamic, Metabolic, and Anesthetic Considerations

Does Anatomic Versus Nonanatomic Resection Affect Recurrence and Survival in Patients Undergoing Surgery for Colorectal Liver Metastasis?

Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation

Synchronous Hepatic Metastases from Colon Cancer: Changing Treatment Strategies and Results of Surgical Intervention